LRRK2 and synucleinopathy: Whilst there are no clinical biomarkers in routine use in PD which correlate with disease progression, accumulation of αSyn oligomers in the brain appears to be a useful marker of synucleinopathy in our LRRK2 mutant mice, which may potentially correlate with progression in the human disease52.